The convergence of multiple signaling pathways - ranging from MET, PI3K/AKT to PERK and EMT - underscored the need for rational combination therapies targeting these alternative routes to effectively combat TKI resistance in RCC. This evidence concerns the gene AKT1 and renal cell carcinoma.